We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AiCuris Presents Preclinical and Phase 1 Data of its Anti-HSV Drug AIC316
News

AiCuris Presents Preclinical and Phase 1 Data of its Anti-HSV Drug AIC316

AiCuris Presents Preclinical and Phase 1 Data of its Anti-HSV Drug AIC316
News

AiCuris Presents Preclinical and Phase 1 Data of its Anti-HSV Drug AIC316

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AiCuris Presents Preclinical and Phase 1 Data of its Anti-HSV Drug AIC316"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AiCuris announced the presentation of preclinical and Phase 1 data on AIC316 at the Antivirals Congress in Amsterdam, Netherlands, from 7th – 9th of November 2010. AIC316 is a novel anti-HSV drug currently in clinical phase 2 testing.

AiCuris scientist and project leader Dr. Alexander Birkmann will give an overview on the pharmacokinetic-pharmacodynamic relationship of AIC316 by presenting efficacy data from experiments performed in a murine infection model and Phase 1 pharmacokinetic data which demonstrate that the predicted efficacious concentrations of AIC316 will be easily achieved in humans.

The oral presentation will be held during Plenary Session 5 on “Antiviral Resistance” scheduled for Monday, November 8, 2010, at 14:40 hrs, NH Grand Hotel Krasnapolsky, Amsterdam.

“The results also clearly confirm that AIC316 has the potential for once daily dosing which we consider as a prerequisite for the intended indication of genital herpes” said Dr. Holger Zimmermann, Chief Scientific Officer of AiCuris. AiCuris’ CEO Prof.

Helga Rübsamen-Schaeff adds: “Genital and labial herpes may be considered as “unimportant” infectious diseases as they are normally self-limiting and there are drugs to treat them. However, we know that patients may suffer tremendously, physically and psychologically and that the unmet medical need is still very high. Therefore we are committed to make a real difference with an innovative and resistance-breaking drug against Herpes simplex."
Advertisement